NEW YORK (AP) — Shares of respiratory drug maker KaloBios Pharmaceuticals are inching higher on the first day of trading.
KaloBios Pharmaceuticals Inc. says its initial public offering of 8.8 million shares priced at $8 per share. The company's stock is now trading on the Nasdaq Global Market under the ticker symbol "KBIO." In early trading the stock gain 9 cents to $8.09.
The underwriters of the offering will have the option to buy another 1.3 million shares to cover any over allotments.
In January KaloBios said it intended to sell 3.9 million shares for $12 to $14 per share.
The company is based in South San Francisco, Calif., and it is studying antibacterial drugs and treatments for cystic fibrosis and blood cancers.
Will progressives flee to web TV if MSNBC bails on them?
- Vladimir Putin’s Russia Adopts Concealed Carry
Hillary Clinton joins union rally in front of Trump hotel
Supreme Court Will Refuse To Hear "Assault Weapons" Ban Case. Here's Why. - Bearing Arms - Assault Weapons Ban, Illinois, Supreme Court
Thomas Sowell - The 'Gun Control' Farce
U.S. Leadership Ushers New Age of Christian Martyrdom | Human Events
The Democratic Debate: Prepare for an Orgy of Unicorn Farts and Pixie Dust | RedState